Any current/future new fundraising through debt or equity?

Currently, there is no immediate plan for new acquisitions or fundraising through equity as the recent QIP of INR 200 crores was primarily for capex and working capital. The company is evaluating multiple acquisition opportunities but will consider them only if they add synergy and align with strategy. No immediate debt raise is planned; Morepen Laboratories is currently a debt-free company. The capital raised in the recent QIP is targeted mainly for capacity expansion in APIs and medical devices. Future fundraising through debt or equity will depend on cash surplus and strategic needs, but no

Any current/future capex/capital investment/strategic investment?

Currently, Morepen Laboratories has planned a capex of INR 123 crores. Of this, approximately INR 78 crores is allocated for API capacity expansion (from 400 KL to 600 KL). Around INR 40-45 crores is earmarked for medical devices, including backward integration and capacity expansion for glucometers, BP monitors, and weighing scales. Backward integration projects, such as chip manufacturing for medical devices, are underway and expected to show results from Q3/Q4 FY '25. The company is focused on expanding distribution reach across India (especially South and West regions) and tapping into glo

Future growth expectations in sales/revenue/volumes?

The company expects to maintain at least 15% to 18% revenue growth. Revenue growth is anticipated to be steady between 15% to 20% annually. Medical devices segment is the fastest growing business, with a CAGR of around 20%-25%, expected to continue. Expansion plans to increase retail outlets from 128,000 to 300,000 across India within three years to boost sales. Focus on backward integration and capacity expansion to support volume growth in glucometers, BP monitors, and APIs. International market penetration is targeted within 2-3 years to significantly enhance growth prospects. N

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects to maintain 15% to 18% revenue growth going forward. EBITDA margins are targeted to improve by 3% to 4% over the next 2-3 years, moving from around 12% currently to approximately 15%. The aim is to reach EBITDA margins of 12% to 15% over the next three years to align with industry norms. Profit After Tax (PAT) is expected to gradually increase towards double-digit levels, with current quarterly PAT at 7.89%. Earnings Per Share (EPS) for the trailing 12 months has risen to INR 2.30, reflecting strong growth. The company is focused on revenue CAGR of 15% to 20%, sup

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Morepen Laboratories Limited. However, there is discussion about capacity expansion plans, including a capex of INR123 crores for APIs and medical devices, indicating anticipation of increased demand. The company mentions being short of capacities, especially in medical devices, which implies strong order inflow. They have increased distribution reach, targeting expansion in Indian markets and exploring exports, suggesting a growing pipeline. No specific figures on order backlog or pending order

Morepen Laboratories LtdQ1 FY25Pharmaceuticals & Biotechnology

Morepen Laboratories Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹119P/E: 56.2Market Cap: ₹6.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company expects to maintain at least 15% to 18% revenue growth.
Revenue growth is anticipated to be steady between 15% to 20% annually.
Medical devices segment is the fastest growing business, with a CAGR of around 20%-25%, expected to continue.
Expansion plans to increase retail outlets from 128,000 to 300,000 across India within three years to boost sales.
Focus on backward integration and capacity expansion to support volume growth in glucometers, BP monitors, and APIs.
International market penetration is targeted within 2-3 years to significantly enhance growth prospects.
New launches planned, including a weight loss OTC product, aiming to capture emerging market segments.
EBITDA margins expected to improve by 3% to 4% over the next 2-3 years, supporting profitability alongside revenue growth.
Export markets, especially Europe and Asia Pacific, showing strong growth potential with ongoing capacity enhancement.

Margin guidance

Category 1

The company expects to maintain 15% to 18% revenue growth going forward.
EBITDA margins are targeted to improve by 3% to 4% over the next 2-3 years, moving from around 12% currently to approximately 15%.
The aim is to reach EBITDA margins of 12% to 15% over the next three years to align with industry norms.
Profit After Tax (PAT) is expected to gradually increase towards double-digit levels, with current quarterly PAT at 7.89%.
Earnings Per Share (EPS) for the trailing 12 months has risen to INR 2.30, reflecting strong growth.
The company is focused on revenue CAGR of 15% to 20%, supported by capacity expansions in APIs and medical devices.
Medical devices segment is expected to grow at a CAGR of 20%-25%.
Overall, the company is on a growth trajectory with steady margin expansion and increasing return on capital employed.

See what Morepen Laboratories Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

Currently, there is no immediate plan for new acquisitions or fundraising through equity as the recent QIP of INR 200 crores was primarily for capex and working capital.
The company is evaluating multiple acquisition opportunities but will consider them only if they add synergy and align with strategy.
No immediate debt raise is planned; Morepen Laboratories is currently a debt-free company.
The capital raised in the recent QIP is targeted mainly for capacity expansion in APIs and medical devices.
Future fundraising through debt or equity will depend on cash surplus and strategic needs, but no specific plans have been announced at this time.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Morepen Laboratories Limited.
However, there is discussion about capacity expansion plans, including a capex of INR123 crores for APIs and medical devices, indicating anticipation of increased demand.
The company mentions being short of capacities, especially in medical devices, which implies strong order inflow.
They have increased distribution reach, targeting expansion in Indian markets and exploring exports, suggesting a growing pipeline.
No specific figures on order backlog or pending orders were provided during the Q&A.

See what Morepen Laboratories Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Currently, Morepen Laboratories has planned a capex of INR 123 crores.
Of this, approximately INR 78 crores is allocated for API capacity expansion (from 400 KL to 600 KL).
Around INR 40-45 crores is earmarked for medical devices, including backward integration and capacity expansion for glucometers, BP monitors, and weighing scales.
Backward integration projects, such as chip manufacturing for medical devices, are underway and expected to show results from Q3/Q4 FY '25.
The company is focused on expanding distribution reach across India (especially South and West regions) and tapping into global export markets.
Though there is no immediate plan for acquisitions, the company remains open to synergistic acquisitions if suitable opportunities arise.
The capital raised through QIP (approx. INR 200 crores) primarily supports these capex plans with a focus on sustained revenue growth (estimated 15%-20% annually) and margin improvement.

Track Morepen Laboratories Ltd — get its next earnings analysis in your feed

How does Morepen Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisMorepen Laboratories Ltd

Rev 3Mar 1

See where Morepen Laboratories Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Morepen Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Morepen Laboratories Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Morepen Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
FDC Ltd (Q3 FY23)
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →